Eli Lilly has developed a new oral medication, orforglipron, which has shown an average weight loss exceeding 12% among individuals with obesity during an 18-month trial. This trial involved over 3,000 adults with an average starting weight of 228 pounds. Participants were given varying doses of orforglipron, leading to the highest dose resulting in about 27 pounds of average loss. The drug mimics a hormone regulating blood sugar and promoting fullness. While generally safe, gastrointestinal side effects were common, particularly nausea and constipation.
Eli Lilly's new oral drug, orforglipron, has demonstrated an average weight loss of over 12% among adults with obesity in its 18-month clinical trial.
In the trial involving over 3,000 adults, the highest dose of orforglipron resulted in about 27 pounds of average weight loss, while the placebo group lost only 2 pounds.
Participants taking orforglipron experienced side effects like nausea and constipation, with nausea reported by one-third of those in the highest-dose group.
Orforglipron is a daily pill aimed at providing an alternative to Eli Lilly’s weekly injectable drug Zepbound for individuals struggling with obesity.
Collection
[
|
...
]